Centanafadine hydrochloride
CAS No. 923981-14-0
Centanafadine hydrochloride( EB-1020 hydrochloride )
Catalog No. M24973 CAS No. 923981-14-0
Centanafadine hydrochloride is a dual inhibitor of norepinephrine (NE)/dopamine (DA) transporter.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 115 | In Stock |
|
10MG | 192 | In Stock |
|
25MG | 385 | In Stock |
|
50MG | 619 | In Stock |
|
100MG | 972 | In Stock |
|
200MG | 1305 | In Stock |
|
500MG | 1944 | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCentanafadine hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionCentanafadine hydrochloride is a dual inhibitor of norepinephrine (NE)/dopamine (DA) transporter.
-
DescriptionCentanafadine hydrochloride is a dual inhibitor of norepinephrine (NE)/dopamine (DA) transporter, also inhibits serotonin transporter (IC50s: 6 nM, 38 nM, and 83 nM for human NE, DA, and serotonin transporter).(In Vitro):Centanafadine (EB-1020) preferentially inhibits monoamine reuptake in cloned cell lines transfected with human transporters with IC50 values of 6 and 38 nM, respectively, for NE and DA transporters, Centanafadine has lesser effects on 5-HT transporter as it inhibits the reuptake of 5-HT with an IC50 value of 83 nM .(In Vivo):In microdialysis studies, Centanafadine markedly increases NE, and DA concentrations levels in rat prefrontal cortex in vivo with peak increases of 375 and 300%, respectively with the greatest effects on NE, and also increases DA extracellular concentrations in the striatum to 400% of baseline concentrations. Behavioral studies demonstrate that Centanafadine dose-dependently decreases immobility in the mouse tail suspension test of depression to 13% of control levels, and do not stimulate locomotor activity in adult rats in the optimal dose range. Centanafadine dose-dependently inhibits locomotor hyperactivity in juvenile rats lesioned with the neurotoxin 6-hydroxydopamine (100 μg intracisternally) as neonates; a well-established animal model for attention-deficit hyperactivity disorder (ADHD).
-
In VitroCentanafadine (EB-1020) preferentially inhibits monoamine reuptake in cloned cell lines transfected with human transporters with IC50 values of 6 and 38 nM, respectively, for NE and DA transporters, Centanafadine has lesser effects on 5-HT transporter as it inhibits the reuptake of 5-HT with an IC50 value of 83 nM .
-
In VivoIn microdialysis studies, Centanafadine markedly increases NE, and DA concentrations levels in rat prefrontal cortex in vivo with peak increases of 375 and 300%, respectively with the greatest effects on NE, and also increases DA extracellular concentrations in the striatum to 400% of baseline concentrations. Behavioral studies demonstrate that Centanafadine dose-dependently decreases immobility in the mouse tail suspension test of depression to 13% of control levels, and do not stimulate locomotor activity in adult rats in the optimal dose range. Centanafadine dose-dependently inhibits locomotor hyperactivity in juvenile rats lesioned with the neurotoxin 6-hydroxydopamine (100 μg intracisternally) as neonates; a well-established animal model for attention-deficit hyperactivity disorder (ADHD).
-
SynonymsEB-1020 hydrochloride
-
PathwayGPCR/G Protein
-
TargetDopamine Receptor
-
Recptordopamine|Norepinephrine (NE)|serotonin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number923981-14-0
-
Formula Weight245.75
-
Molecular FormulaC15H16ClN
-
Purity>98% (HPLC)
-
SolubilityDMSO:125 mg/mL (508.65 mM; Need ultrasonic)
-
SMILES[H][C@@]12CNC[C@]1(C3=CC=C4C=CC=CC4=C3)C2.[H]Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Bymaster FP, et al. Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder. Synapse. 2012 Jun;66(6):522-32.
molnova catalog
related products
-
FIIN-2
FIIN-2, an irreversible, pan-FGFR inhibitor, inhibits FGFR1/2/3/4 with IC50 of 3.09 nM, 4.3 nM, 27 nM and 45.3 nM, respectively.
-
GSK598809
GSK598809 (GSK-598809) is a potent, selective, CNS penetrant and orally bioavailable dopamine D3 receptor antagonist with pKi of 8.9; displays >100-fold selectivity over D2 and H1 receptors.
-
Pramipexole dihydroc...
A partial/full agonist of dopamine receptor with Ki of 3.9/2.2/0.5/5.1 nM for D2S/D2L/D3/D4, respeectively.